Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters

Sci Rep. 2017 Mar 23:7:44872. doi: 10.1038/srep44872.

Abstract

Parkinson disease (PD) is identified as tremor-dominant (TD) and postural instability and gait difficulty (PIGD) phenotypes. The relationships between motor phenotypes and cognitive impairment and the underlying mechanisms relating pathological proteins and neurotransmitters in cerebrospinal fluid (CSF) are unknown. We evaluated the motor symptoms and cognitive function by scales, and detected the levels of pathological proteins and neurotransmitters in CSF. TD group and PIGD group had significantly higher levels of total tau, tau phosphorylated at the position of threonine 181(P-tau181t), threonine 231, serine 396, serine 199 and lower β amyloid (Aβ)1-42 level in CSF than those in control group; PIGD group had significantly higher P-tau181t level and lower Aβ1-42 level than those in TD group. In PD group, PIGD severity was negatively correlated with MoCA score and Aβ1-42 level in CSF, and positively correlated with Hoehn-Yahr stage and P-tau181t level in CSF. In PIGD group, PIGD severity was negatively correlated with homovanillic acid (HVA) level in CSF, and HVA level was positively correlated with Aβ1-42 level in CSF. PIGD was significantly correlated with cognitive impairment, which underlying mechanism might be involved in Aβ1-42 aggregation in brain and relevant neurochemical disturbance featured by the depletion of HVA in CSF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amyloid beta-Peptides / metabolism
  • Biomarkers
  • Case-Control Studies
  • Cognition
  • Cognitive Dysfunction / diagnosis
  • Cognitive Dysfunction / etiology
  • Female
  • Gait Disorders, Neurologic / diagnosis*
  • Gait Disorders, Neurologic / etiology*
  • Humans
  • Male
  • Middle Aged
  • Motor Activity
  • Neuropsychological Tests
  • Neurotransmitter Agents / metabolism
  • Parkinson Disease / complications*
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / metabolism
  • Peptide Fragments / metabolism
  • Phenotype*
  • Sensation Disorders / diagnosis*
  • Sensation Disorders / etiology*
  • Severity of Illness Index
  • tau Proteins / metabolism

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Neurotransmitter Agents
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins